Key Metrics
0.2
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Q4
Pharmacology
SJR
- Q4 Pharmacology
- Q4 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.06
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Medical genetics
- Receptor antagonist
- Molecular targets
- Monoclonal antibody
- Topoisomerase
- Cancer immunotherapy
- DNA Gyrase Inhibitors
- Calcitonin gene-related peptide
- RNA polymerase
- Anaphylatoxin C5a
- Resistant hypertension
- Margetuximab
- Autism spectrum disorder
- Cancer research
- Cytochrome b
- Calcitonin gene-related peptide receptor antagonist
- Drug discovery
- Cancer therapy
- Antibody-drug conjugate
- Dipeptidyl peptidase
Journal Specifications
| Overview | |
| Publisher | PROUS SCIENCE, SAU-THOMSON REUTERS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1976 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Drugs of the Future ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 2022
- 1 Mar 23
- Drugs of The Future
-
Full paper
Pipeline on the Move
- 1 Mar 23
- Drugs of The Future
-
Full paper
Spesolimab. Anti-IL-36R monoclonal antibody, Treatment of generalized pustular psoriasis, Treatment of immune-mediated inflammatory diseases
- 1 Mar 23
- Drugs of The Future
-
Full paper
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 2022
- 1 Mar 23
- Drugs of The Future
-
Full paper
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity
- 1 Mar 23
- Drugs of The Future
-
Full paper
Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma
- 1 Mar 23
- Drugs of The Future
Scite analysis
Powered by scite_
6.5k articles received 5.2k citations see all
- 86 Supporting
- 5,046 Mentioning
- 4 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Drugs of the Future been actively publishing?
Drugs of the Future has been in operation since 1976 till date.
What is the publishing frequency of Drugs of the Future ?
Drugs of the Future published with a Monthly frequency.
How many articles did Drugs of the Future publish last years ?
In 2023, Drugs of the Future published 25 articles.
What is the eISSN & pISSN for Drugs of the Future ?
For Drugs of the Future,eISSN is 2013-0368 and pISSN is0377-8282.
What is Citescore for Drugs of the Future ?
Citescore for Drugs of the Future is 0.2.
What is SNIP score for Drugs of the Future ?
SNIP score for Drugs of the Future is 0.06.
What is the SJR for Drugs of the Future ?
SJR for Drugs of the Future is Q4.
Who is the publisher of Drugs of the Future ?
PROUS SCIENCE, SAU-THOMSON REUTERS is the publisher of Drugs of the Future.